Skip to main content
Joost Kluiver
dr.

I have a central role in all research projects focusing on the role of noncoding RNAs. My main aim is to understanding how small and long non-coding RNAs contribute to the pathogenesis of B-cell lymphoma. Ongoing studies include MYC-regulated miRNAs and lncRNAs, as well as miRNA-lncRNA interactions and the role of circular RNAs. We apply state-of-the-art methodology including AGO2-RIP, RNA-FISH and gain- and loss-of-function screens using shRNA and CRISPR-Cas technology.

A population-based study of transformed marginal zone lymphoma: identifying outcome-related characteristics
Published in: Blood cancer journal
Access to document 10.1038/s41408-023-00903-w document
Histological transformation of marginal zone lymphoma (tMZL) into diffuse large B-cell lymphoma is associated with poor outcomes. Clinical characteristics associated with transformation risk and outcome after transformation are largely unknown due to scarcity of data. In this population-based study, competing risk analyses were performed to elucidate clinical characteristics associated with developing transformation among 1793 MZL patients using the Netherlands Cancer Registry. Cox regression analyses were performed to elucidate clinical characteristics associated with risk of relapse and mortality after transformation. Transformation occurred in 75 (4%) out of 1793 MZL...
Johanna A A Bult, Francien Huisman, Yujie Zhong, Nick Veltmaat, Joost Kluiver, Sanne H Tonino, Joost S P Vermaat, Martine E D Chamuleau, Arjan Diepstra, Anke van den Berg, Wouter J Plattel, Mirian Brink, Marcel Nijland
CRISPR/Cas9 screen for genome-wide interrogation of essential MYC-bound E-boxes in cancer cells
Published in: Molecular oncology
Access to document 10.1002/1878-0261.13493 document
The transcription factor MYC is a proto-oncogene with a well-documented essential role in the pathogenesis and maintenance of several types of cancer. MYC binds to specific E-box sequences in the genome to regulate gene expression in a cell-type- and developmental-stage-specific manner. To date, a combined analysis of essential MYC-bound E-boxes and their downstream target genes important for growth of different types of cancer is missing. In this study, we designed a CRISPR/Cas9 library to destroy E-box sequences in a genome-wide fashion. In parallel, we used the Brunello library...
Marta Kazimierska, Marta Podralska, Magdalena Żurawek, Tomasz Woźniak, Marta Elżbieta Kasprzyk, Weronika Sura, Wojciech Łosiewski, Iwona Ziółkowska-Suchanek, Joost Kluiver, Anke van den Berg, Natalia Rozwadowska, Agnieszka Dzikiewicz-Krawczyk
Long non-coding RNAs associated with transcriptomic signatures and treatment outcome in diffuse large B-cell lymphoma
Published in: British Journal of Haematology
Access to document 10.1111/bjh.18870 document
Gerben Duns, Melanie Winkle, Lauren Chong, Daisuke Ennishi, Ryan D Morin, Arjan Diepstra, David W Scott, Joost L Kluiver, Christian Steidl, Anke van den Berg
The lncRNA KTN1-AS1 co-regulates a variety of Myc-target genes and enhances proliferation of Burkitt lymphoma cells
Published in: Human Molecular Genetics
Access to document 10.1093/hmg/ddac159 document
Long noncoding RNAs (lncRNAs) are involved in many normal and oncogenic pathways through a diverse repertoire of transcriptional and posttranscriptional regulatory mechanisms. LncRNAs that are under tight regulation of well-known oncogenic transcription factors such as c-Myc (Myc) are likely to be functionally involved in their disease-promoting mechanisms. Myc is a major driver of many subsets of B cell lymphoma and to date remains an undruggable target. We identified three Myc-induced and four Myc-repressed lncRNAs by use of multiple in vitro models of Myc-driven Burkitt lymphoma and detailed analysis...
Melanie Winkle, Mina M Tayari, Klaas Kok, Gerben Duns, Natalia Grot, Marta Kazimierska, Annika Seitz, Debora Jong, Jasper Koerts, Arjan Diepstra, Agnieszka Dzikiewicz-Krawczyk, Christian Steidl, Joost Kluiver, Anke van den Berg
Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature
Published in: Clinical lung cancer
Access to document 10.1016/j.cllc.2021.06.011 document
INTRODUCTION: Non-small cell lung cancer (NSCLC) patients with Anaplastic Lymphoma Kinase (ALK) gene fusions respond well to ALK inhibitors but commonly develop on-target resistance mutations. The objective of this study is to collect clinical evidence for subsequent treatment with ALK inhibitors. PATIENTS AND METHODS: Local experience with on-target ALK resistance mutations and review of the literature identified 387 patients with ALK inhibitor resistance mutations. Clinical benefit of mutation-inhibitor combinations was assessed based on reported response, progression-free survival and duration of treatment. Furthermore, this clinical evidence was compared to...
Bart Koopman, Harry J. M. Groen, Ed Schuuring, Jeroen Hiltermann, Wim Timens, Wilfred F. A. den Dunnen, A. van den Berg, Arja ter Elst, Michel van Kruchten, Joost Kluiver, Birgitta Hiddinga, Lucie Hijmering-Kappelle, Matthew Groves, Juliana Vilachá Madeira R Santos, Léon van Kempen, A. J. van der Wekken